Management of soft-tissue sarcomas: An overview and update

Lancet Oncology

Volumn 1, Issue 2, 2000, Pages 75-85

  Singer, Samuel ^a   Demetri, George D ^b   Baldini, Elizabeth H ^a   Fletcher, Christopher D M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHROMOSOME ABERRATION; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; SARCOMA;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; HUMANS; SARCOMA;

EID: 0034308908     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00016-4     Document Type: Review

References (50)

1. Clasby R, Tilling K, Smith MA, Fletcher CDM. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997; 84: 1692-96.
2. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomised evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196: 305-15.
3. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival. J Clin Oncol 1994; 12: 1137-49.
4. Chang AE, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high grade soft tissue sarcomas of the extremity. J Clin Oncol 1988; 6: 1491-500.
5. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647-54.
6. Gustafson P. Soft tissue sarcoma: epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994; 65 (suppl 259): 1-31.
7. Pisters PWT, Leung DHY, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-89.
8. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1997; 15: 646-52.
9. Espat NJ, Lewis JJ. The biological significance of failure at the primary site on ultimate survival in soft tissue sarcoma. Semin Radiat Oncol 1999; 9: 369-77.
10. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg 1999; 229: 602-12.
11. Rydholm A, Gustafson P, Röoser B, et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol 1991; 9: 1757-65.
12. Baldini E, Goldberg J, Jenner C, et al. Long-term outcomes following function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999; 17: 3252-59.
13. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203.
14. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995; 221: 185-95.
15. Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma. Ann Surg 1991: 214: 2-10.
16. Bevilacqua RG, Rogatko A, Hajdu SI, et al. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg 1991; 126: 328-34.
17. Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retropertoneal sarcoma: implications for management. J Clin Oncol 1997; 15: 2837-39.
18. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228: 335-65.
19. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of soft tissue sarcomas. Mod Pathol 1998; 11: 1257-61.
20. Fletcher CDM. Soft tissue tumors. In: Fletcher CDM, ed. Diagnostic histopathology of tumors, 2nd ed. Edinburgh: Churchill Livingstone, 2000: 1473-540.
21. Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based upon 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992; 16: 213-28.
22. Guillou L, Coindre J-M, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-62.
23. Brown FM, Fletcher CDM. Problems in grading soft tissue sarcomas. Am J Clin Pathol 2000 (in press).
24. Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with MO soft tissue sarcoma. J Clin Oncol 1988; 6: 854-62.
25. Schray MF, Gunderson LL, Sim F, Pritchard DJ, Shives TC, Yeakel RTT. Soft tissue sarcoma - integration of brachytherapy, resection and external radiation. Cancer 1990; 66: 451-56.
26. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219: 165-73.
27. Pisters PWT, Harrison LB, Leung DHY, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14: 859-68.
28. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft tissue tumors. Cancer 1982; 49: 1721-33.
29. Gibbs CP, Peabody TD, Mundt AJ, Montag AG, Simon MA. Oncological outcomes of operative treatment of subcutaneous soft tissue sarcomas of the extremities. J Bone Joint Surg Am 1997; 79: 888-97.
30. Pezzi CM, Rawlings MS, Esgro JJ, et al. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer 1992; 69: 2098-103.
31. Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 2000; 47: 1273-79.
32. Zelefsky MJ, Nori D, Shiu MH, Brennan MF. Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytherapy. Int J Radiat Oncol Biol Phys 1990; 19: 913-18.
33. Pearlstone DB, Janjan NA, Feig BW, et al. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. Cancer J Sci Am 1999; 5: 26-33.
34. Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective randomized clinical trial. Arch Surg 1993; 128: 402-10.
35. Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 2000; 47: 157-63.
36. Karasek K, Constine LS, Rosier R. Sarcoma therapy: functional outcome and relationship to treatment parameters. Int J Radiat Oncol Biol Phys 1992; 24: 651-56.
37. Stinson SF, Delaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1990; 21: 1493-99.
38. Raney RB, Asmar L, Newton WA Jr, et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972-1991. J Clin Oncol 1997; 15: 574-82.
39. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-30.
40. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematol Oncol Clin North Am 1995: 9: 765-85.
41. Patel SR, Vadhan-Raj S, Papadopoulos NJ, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
42. Frustaci S, Gherlinzoni F, De Paoli A, et al. Maintenance of efficacy of adjuvant chemotherapy (CT) in soft tissue sarcoma (STS) of the extremities up-date of a randomized trial. Proc Am Soc Clin Oncol 1999; 18: 546a (abstr).
43. Benjamin RS, Rouesse J, Bourgeois H, van Hoesel QGCM. Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 1998; 34: 958-65.
44. Antman KH, Crowley J, Balcerzak SP, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-85.
45. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237-41.
46. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-56.
47. Demetri GD, Seiden M, Garcia-Carbonero R, et al. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 U.S.-based phase II trials. Proc Am Soc Clin Oncol 2000; 19: 553a (abstr).
48. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimes - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-57.
49. Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 2000; 18: 1637-43.
50. Trovik CS, Bauer HCF, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000; 36: 710-716.